We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
Results 1 to 5 of 15
Most popular |Most recent

Top 10 steps global life sciences companies should take in 2014

USA - February 24 2014 Prepare now for difficult-to-defend challenges to biological patents. Most innovative biological product companies have little experience with the...

Paul E. Kalb, Scott Bass, James C. Stansel.

Ten Steps Life Sciences Companies Should Take to Address Global Challenges in 2016

Global - January 7 2016 New pricing regimes in the EU and China are heavily focused on comparative effectiveness, while the U.S. will also see new cost-constraining...

U.S. Congress Reauthorizes Food and Drug Administration User Fee Programs, Acts on Other FDA Measures

USA - August 15 2017 After more than two years of negotiations and just before the summer recess, the Senate voted to reauthorize the Food and Drug Administration's (FDA)...

Coleen Klasmeier, Nancy K. Stade, Brigid DeCoursey Bondoc.

A year of global change 2015: 10 steps multinational life sciences companies should take to address global challenges

Global - March 2 2015 Members of Sidley Austin's Global Life Sciences team recently reviewed litigation, policy, regulatory and enforcement trends on several continents...

FDA Considers Removing Regulatory Obstacles to Generic Drug Competition

USA - August 1 2017 On July 18, 2017, the Food and Drug Administration (FDA) held a public meeting1 to obtain input on steps it can take to encourage innovation in drug...

Coleen Klasmeier, Tina Papagiannopoulos.